| Safety and efficacy of nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: results from the phase I/II CheckMate 358 trial RW Naumann, A Hollebecque, T Meyer, MJ Devlin, A Oaknin, J Kerger, ... Journal of Clinical Oncology 37 (31), 2825, 2019 | 344 | 2019 |
| An open-label, multicohort, phase I/II study of nivolumab in patients with virus-associated tumors (CheckMate 358): Efficacy and safety in recurrent or metastatic (R/M … A Hollebecque, T Meyer, KN Moore, JPH Machiels, J De Greve, ... Journal of Clinical Oncology 35 (15_suppl), 5504-5504, 2017 | 117 | 2017 |
| Abstract CT074: Non-comparative, open-label, multiple cohort, phase 1/2 study to evaluate nivolumab (NIVO) in patients with virus-associated tumors (CheckMate 358): Efficacy … SL Topalian, S Bhatia, A Hollebecque, A Awada, JPD Boer, ... Cancer Research 77 (13_Supplement), CT074-CT074, 2017 | 99 | 2017 |
| Non-comparative, open-label, multiple cohort, phase 1/2 study to evaluate nivolumab (NIVO) in patients with virus-associated tumors (CheckMate 358): efficacy and safety in … SL Topalian, S Bhatia, A Hollebecque, A Awada, JP De Boer, ... Cancer Research 77, 2017 | 77 | 2017 |
| An open-label, multicohort, phase 1/2 study in patients with virus-associated cancers (CheckMate 358): safety and efficacy of neoadjuvant nivolumab in squamous cell carcinoma … RL Ferris, A Gonçalves, SS Baxi, UM Martens, H Gauthier, M Langenberg, ... Annals of oncology 28, v628-v629, 2017 | 57 | 2017 |
| Nivolumab (nivo) as neoadjuvant therapy in patients with resectable Merkel cell carcinoma (MCC) in CheckMate 358. SL Topalian, S Bhatia, RR Kudchadkar, A Amin, WH Sharfman, C Lebbe, ... Journal of Clinical Oncology 36 (15_suppl), 9505-9505, 2018 | 49 | 2018 |
| An open-label, multicohort, phase I/II study to evaluate nivolumab in patients with virus-associated tumors (CheckMate 358): Efficacy and safety in recurrent or metastatic (R/M … JP Delord, A Hollebecque, JP De Boer, J De Greve, JPH Machiels, ... Journal of Clinical Oncology 35 (15_suppl), 6025-6025, 2017 | 33 | 2017 |
| 723MO Tisotumab vedotin (TV)+ carboplatin (Carbo) in first-line (1L) or+ pembrolizumab (Pembro) in previously treated (2L/3L) recurrent or metastatic cervical cancer (r/mCC … IB Vergote, BJ Monk, RE O’Cearbhaill, AM Westermann, S Banerjee, ... Annals of Oncology 32, S726-S727, 2021 | 22 | 2021 |
| Tisotumab vedotin (TV)+ pembrolizumab (pembro) in first-line (1L) recurrent or metastatic cervical cancer (r/mCC): Interim results of ENGOT Cx8/GOG 3024/innovaTV 205. D Lorusso, I Vergote, RE O'Cearbhaill, AM Westermann, SN Banerjee, ... Journal of clinical oncology 40 (16_suppl), 5507-5507, 2022 | 21 | 2022 |
| LBA9 innovaTV 301/ENGOT-cx12/GOG-3057: A global, randomized, open-label, phase III study of tisotumab vedotin vs investigator’s choice of chemotherapy in 2L or 3L recurrent or … IB Vergote, AG Martin, K Fujiwara, E Kalbacher, A Bagameri, ... Annals of Oncology 34, S1276-S1277, 2023 | 17 | 2023 |
| Tisotumab vedotin in Japanese patients with recurrent/metastatic cervical cancer: Results from the innovaTV 206 study K Yonemori, Y Kuboki, K Hasegawa, T Iwata, H Kato, K Takehara, ... Cancer science 113 (8), 2788-2797, 2022 | 14 | 2022 |
| Phase I/II trial of tisotumab vedotin plus bevacizumab, pembrolizumab, or carboplatin in recurrent or metastatic cervical cancer (innovaTV 205/ENGOT-cx8) IB Vergote, N Concin, MR Mirza, A Malmberg, L Eaton, L Nicacio, ... Annals of Oncology 30, v433-v434, 2019 | 10 | 2019 |
| 617 Tisotumab vedotin shows immunomodulatory activity through induction of immunogenic cell death E Gray, K Hensley, S Allred, E Trueblood, J Gosink, R Thurman, K Smith, ... Journal for ImmunoTherapy of Cancer 8 (Suppl 3), 2020 | 8 | 2020 |
| Phase Ib/II trial of tisotumab vedotin (TV)±bevacizumab (BEV), pembrolizumab (PEM), or carboplatin (CBP) in recurrent or metastatic cervical cancer (innovaTV 205/ENGOT-cx8/GOG … I Vergote, N Concin, MR Mirza, CM Andreassen, D Lorusso, ... Journal of Clinical Oncology 38 (15_suppl), TPS6095-TPS6095, 2020 | 7 | 2020 |
| Tisotumab vedotin in combination with carboplatin, pembrolizumab, or bevacizumab in recurrent or metastatic cervical cancer: results from the innovaTV 205/GOG-3024/ENGOT-cx8 study I Vergote, E Van Nieuwenhuysen, RE O'Cearbhaill, A Westermann, ... Journal of clinical oncology 41 (36), 5536-5549, 2023 | 6 | 2023 |
| Abstract CT164: Tisotumab vedotin (TV) in squamous cell carcinoma of head and neck (SCCHN): interim analysis from innovaTV 207 B Cirauqui, S Salas, W William, AE Birnbaum, K Schmidt, X Guan, ... Cancer Research 83 (8_Supplement), CT164-CT164, 2023 | 4 | 2023 |
| Trial in progress update on ENGOT-cx8/GOG-3024/innovaTV 205: Addition of a new cohort with first-line (1L) tisotumab vedotin (TV)+ pembrolizumab (pembro)+ carboplatin (carbo … I Vergote, MR Mirza, J Sehouli, D Lorusso, F Köse, D Cibula, ... Journal of clinical oncology 40 (16_suppl), TPS5603-TPS5603, 2022 | 4 | 2022 |
| Tisotumab vedotin versus investigator’s choice chemotherapy in second-or third-line recurrent or metastatic cervical cancer (innovaTV 301/ENGOT-cx12/GOG 3057, trial in progress). I Vergote, BJ Monk, RL Coleman, LM Randall, K Fujiwara, C Marth, ... Journal of clinical oncology 39 (15_suppl), TPS5596-TPS5596, 2021 | 4 | 2021 |
| 882TiP InnovaTV 208: New weekly dosing cohort in the phase II study of tisotumab vedotin in platinum-resistant ovarian cancer S Blank, H Mahdi, O Tehrani, S Ghamande, S Jain, L Nicacio, I Soumaoro, ... Annals of Oncology 31, S646, 2020 | 4 | 2020 |
| Efficacy and safety of tisotumab vedotin in patients with head and neck squamous cell carcinoma: results from a phase II cohort DS Hong, A Birnbaum, C Steuer, M Taylor, TJ George, J Lacy, B Wang, ... International Journal of Radiation Oncology, Biology, Physics 112 (5), e10-e11, 2022 | 3 | 2022 |
